The U.S. interventional cardiology and peripheral market size was estimated at USD 7.9 billion in 2024 and is projected to reach USD 13.1 billion by 2033, growing at a CAGR of 5.8% from 2025 to 2033. The growth is driven by the growing burden of cardiovascular and peripheral vascular diseases, rising preference for minimally invasive procedures, and continuous advancements in device technology.
The increasing geriatric population, higher rates of diabetes and hypertension, and supportive reimbursement policies further fuel market expansion. As more primary care professionals and specialists adopt proactive screening protocols, referral rates to interventionalists have increased. Integrating preventive care with interventional therapies drives a shift in treatment paradigms, positioning minimally invasive techniques as first-line interventions in many clinical scenarios. This progression continues to support the market's expansion across coronary and peripheral segments.
An aging population's demographic trend is pronounced, affecting interventional cardiology and peripheral care markets. In January 2024, the Population Reference Bureau released a fact sheet highlighting the unprecedented growth of the U.S. population aged 65 and older, projected to increase by 47% by 2050. It also noted the rising racial and ethnic diversity among older Americans, with a significant shift expected by mid-century. Older adults often present with multiple comorbidities that make them less suitable for invasive surgical procedures, increasing reliance on catheter-based solutions. These minimally invasive techniques provide a viable alternative for managing vascular blockages and related complications in high-risk patients, with a focus on maintaining quality of life.
Advancements in interventional cardiology devices are reshaping clinical decision-making and procedural outcomes. Newer generations of stents, balloons, and adjunctive tools are designed to improve precision, reduce complications, and enhance long-term vessel patency. These innovations enable physicians to address increasingly complex lesions and expand the pool of eligible patients. Improved deliverability and trackability have made devices more versatile across challenging anatomies. In January 2024, AngioDynamics received FDA 510(k) clearance for its Auryon XL Radial Access Catheter, designed for treating Peripheral Arterial Disease (PAD). The catheter expands treatment options, reduces bleeding risks, and accelerates recovery by utilizing radial access, offering a safer alternative to femoral access in atherectomy procedures.
The introduction of intravascular imaging tools and physiology-guided assessment techniques has added a layer of procedural accuracy. These tools support better visualization and decision-making during interventions, contributing to higher procedural success rates. In the peripheral space, technologies such as atherectomy systems and drug-coated devices have effectively treated long or calcified lesions with reduced need for repeat interventions. In February 2024, Biotronik and IMDS launched the Micro Rx Rapid Exchange Microcatheter in the U.S. This advanced device enhances guidewire support, offering improved push transfer and a tapered tip for better penetration. Designed for percutaneous coronary interventions, it aims to reduce procedure time and minimize vascular trauma, addressing challenges in complex vascular anatomies.
This product will be delivered within 2 business days.
The increasing geriatric population, higher rates of diabetes and hypertension, and supportive reimbursement policies further fuel market expansion. As more primary care professionals and specialists adopt proactive screening protocols, referral rates to interventionalists have increased. Integrating preventive care with interventional therapies drives a shift in treatment paradigms, positioning minimally invasive techniques as first-line interventions in many clinical scenarios. This progression continues to support the market's expansion across coronary and peripheral segments.
An aging population's demographic trend is pronounced, affecting interventional cardiology and peripheral care markets. In January 2024, the Population Reference Bureau released a fact sheet highlighting the unprecedented growth of the U.S. population aged 65 and older, projected to increase by 47% by 2050. It also noted the rising racial and ethnic diversity among older Americans, with a significant shift expected by mid-century. Older adults often present with multiple comorbidities that make them less suitable for invasive surgical procedures, increasing reliance on catheter-based solutions. These minimally invasive techniques provide a viable alternative for managing vascular blockages and related complications in high-risk patients, with a focus on maintaining quality of life.
Advancements in interventional cardiology devices are reshaping clinical decision-making and procedural outcomes. Newer generations of stents, balloons, and adjunctive tools are designed to improve precision, reduce complications, and enhance long-term vessel patency. These innovations enable physicians to address increasingly complex lesions and expand the pool of eligible patients. Improved deliverability and trackability have made devices more versatile across challenging anatomies. In January 2024, AngioDynamics received FDA 510(k) clearance for its Auryon XL Radial Access Catheter, designed for treating Peripheral Arterial Disease (PAD). The catheter expands treatment options, reduces bleeding risks, and accelerates recovery by utilizing radial access, offering a safer alternative to femoral access in atherectomy procedures.
The introduction of intravascular imaging tools and physiology-guided assessment techniques has added a layer of procedural accuracy. These tools support better visualization and decision-making during interventions, contributing to higher procedural success rates. In the peripheral space, technologies such as atherectomy systems and drug-coated devices have effectively treated long or calcified lesions with reduced need for repeat interventions. In February 2024, Biotronik and IMDS launched the Micro Rx Rapid Exchange Microcatheter in the U.S. This advanced device enhances guidewire support, offering improved push transfer and a tapered tip for better penetration. Designed for percutaneous coronary interventions, it aims to reduce procedure time and minimize vascular trauma, addressing challenges in complex vascular anatomies.
U.S. Interventional Cardiology And Peripheral Market Report Segmentation
This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, the analyst has segmented the U.S. interventional cardiology and peripheral market report based on product, and application:Product Outlook (Revenue, USD Million, 2021 - 2033)
- Interventional Catheters
- Microcatheters
- Support Microcatheters
- Delivery Microcatheters
- Others
- Guidewires
- Peripheral Stents
- Self-expanding
- Balloon-expandable
- Drug-eluting Stents
- Coronary Stents
- Bioabsorbable Stents
- Drug-Eluting Stents
- Bare Metal Stents
- PTCA Balloon Catheters
- Atherectomy Devices
- Chronic Total Occlusion Devices
- Synthetic Surgical Grafts
- Embolic Protection Devices
- IVC Filters
- PTA Balloon Catheters
- Thrombectomy Devices
Application Outlook (Revenue, USD Million, 2021 - 2033)
- Angioplasty
- Congenital Heart Defect Correction
- Thrombectomy
- Valvuloplasty
- Percutaneous Valve Repair
- Others
Why should you buy this report?
- Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players worldwide.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the global market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listing for you to stay ahead of the curve
- COVID-19's impact and how to sustain in these fast-evolving markets
This product will be delivered within 2 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. U.S. Interventional Cardiology and Peripheral Market Variables, Trends & Scope
Chapter 4. U.S. Interventional Cardiology and Peripheral Market: Product Estimates & Trend Analysis
Chapter 5. U.S. Interventional Cardiology and Peripheral Market: Application Estimates & Trend Analysis
Chapter 6. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
- B. Braun SE
- BD
- Cardinal Health
- Medtronic
- Teleflex Incorporated
- W. L. Gore & Associates Inc.
- Cook
- Boston Scientific Corporation
- AngioDynamics
- Abbott
- OrbusNeich Medical Group Holdings Limited
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 160 |
| Published | July 2025 |
| Forecast Period | 2024 - 2033 |
| Estimated Market Value ( USD | $ 7.9 Billion |
| Forecasted Market Value ( USD | $ 13.1 Billion |
| Compound Annual Growth Rate | 5.8% |
| Regions Covered | United States |
| No. of Companies Mentioned | 11 |
